Eisai will seek approval from China for its new liver cancer drug Lenvima and plans to submit the drug for approval to Western countries this month. China is preparing to accept multiregional clinical data, which would significantly speed the approval process for new drugs.
Eisai to seek Chinese approval for liver cancer drug
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.